Home » Onyx Initiates Phase I Study for Advanced Solid Tumors
Onyx Initiates Phase I Study for Advanced Solid Tumors
Onyx Pharmaceuticals, Inc. announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, as a potential treatment for advanced solid tumors.
News Blaze
News Blaze
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May